CD274 and neoplasm: Characterization of PD-L1 expression on tumor-infiltrating immune cells is already used to predict response to immune checkpoint inhibitors [43], but more comprehensive characterization of the microenvironment will likely provide even deeper insights for patient stratification and drug development.